Corvus Pharmaceutical News Today

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Free Report) – Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($0.35) per share for the year, up from their prior estimate of […]

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) and Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation. Analyst Recommendations This is a summary of […]

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) and Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk. Profitability This table compares ProQR Therapeutics and […]

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) had its price objective hoisted by Cantor Fitzgerald from $2.00 to $4.00 in a research note released on Tuesday, The Fly reports. Cantor Fitzgerald also issued estimates for Corvus Pharmaceuticals’ FY2023 earnings at ($0.41) EPS. CRVS has been the topic of several other reports. Mizuho reiterated a neutral rating […]

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) – Equities researchers at Cantor Fitzgerald upped their FY2023 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a research report issued on Tuesday, May 9th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($0.41) per share for the year, up from […]

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) – Investment analysts at Cantor Fitzgerald lifted their FY2023 EPS estimates for Corvus Pharmaceuticals in a research note issued on Wednesday, March 29th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings of ($0.48) per share for the year, up from their previous forecast […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Pharmaxis (OTCMKTS:PXSLY – Get Rating) and Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Institutional and Insider Ownership 77.9% of Corvus Pharmaceuticals shares are […]